BioCryst Pharmaceuticals reported $218.25M in Sales Revenues for its fiscal quarter ending in June of 2026.





Sales Change Date
Alnylam Pharmaceuticals USD 1.46B 170M Sep/2026
BioCryst Pharmaceuticals USD 218.25M 188.3M Jun/2026
Chugai Pharma JPY 404.7B 63.1B Sep/2026
Daiichi Sankyo JPY 592.49B 17.75B Sep/2026
DBV Technologies USD 1.6M 955K Sep/2026
Enanta Pharmaceuticals USD 16.96M 50.68M Dec/2024
Gilead Sciences USD 8.3B 500M Sep/2026
GlaxoSmithKline GBP 8.89B 480M Sep/2026
Glaxosmithkline GBP 8.89B 1.2B Sep/2026
Incyte USD 1.56B 110M Sep/2026
Ionis Pharmaceuticals USD 243M 25M Sep/2026
Karyopharm Therapeutics USD 35.07M 987K Mar/2026
Neurocrine Biosciences USD 1.12B 161M Sep/2026
Novavax USD 147.14M 76.69M Dec/2025
PTC Therapeutics USD 357.8M 3.2M Sep/2026
Regeneron Pharmaceuticals USD 5.12B 830M Sep/2026
Roche Holding CHF 30.36B 14.71B Jun/2026
Sarepta Therapeutics USD 381.4M 19.9M Sep/2026
Ultragenyx Pharmaceutical USD 173M 41M Sep/2026
Vertex Pharmaceuticals USD 3.44B 110M Sep/2026